Search
BLX-883
go.drugbank.com/drugs/DB05904InvestigationalBLX-883 is a form of alfa interferon developed by Biolex for the treatment of hepatitis viral C.
NSI-566
go.drugbank.com/drugs/DB17954InvestigationalDeveloped by Seneca Biopharma, it is being investigated for the treatment of amyotrophic lateral sclerosis (ALS), stroke, and chronic spinal cord injury (cSCI).[L47097]
Drozitumab
go.drugbank.com/drugs/DB19106InvestigationalIt was developed by Genentech as a drug for the treatment of cancers
(R)-warfarin
go.drugbank.com/drugs/DB08496ExperimentalWarfarin consists of a racemic mixture of two active enantiomers—R- and S- forms—each of which is cleared by different pathways.
Categories: Vitamin K AntagonistsSB-269970
go.drugbank.com/drugs/DB13988ExperimentalSB-269970 is an experimental drug developed by GlaxoSmithKline.
Prostaglandin D2
go.drugbank.com/drugs/DB02056ExperimentalIt is released upon activation of mast cells and is also synthesized by alveolar macrophages.
Irampanel
go.drugbank.com/drugs/DB21123InvestigationalIrampanel is under investigation in clinical trial NCT02222961 (Single Increasing Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Male Volunteers).
AVR-RD-02
go.drugbank.com/drugs/DB17650InvestigationalAVR-RD-02 is an investigational _ex vivo_ lentiviral gene therapy developed by AVROBIO Inc. … It consists of autologous CD34+ enriched hematopoietic stem cells (HSCs) that have been genetically modified _ex vivo_ with a lentiviral vector (LV) to contain a ribonucleic acid (RNA) transcript that,
AV-COVID-19
go.drugbank.com/drugs/DB15802InvestigationalThe vaccine was developed and tested by Aivita Biomedical, Inc.. As of July 2020, the company is pursuing an adaptive Phase IB-II Randomized Clinical Trial (NCT04386252) to test the vaccine. … The monocytes are then differentiated in vitro into dendritic cells with IL-4 and GM-CSF, incubated with SARS-CoV-2 antigens prior to administration.
Rocatinlimab
go.drugbank.com/drugs/DB18809InvestigationalThe drug works by targeting the OX40 receptor, which plays a role in the immune response associated with atopic dermatitis. … In clinical trials, it has shown significant efficacy and safety compared to a placebo.